MaxWell Biosystems raises €3.7M Series A round
17 December 2020· Zurich, Switzerland· health, neuroscience, biotech, microelectronics, software_hardware, b2b
The funds will enable the startup to further industrialise and scale-up the production of their HD-MEA plates, allowing customers in the pharmaceutical industry to run functional drug screenings at a higher throughput and accelerate drug development targeting the brain.
Investors
LeadSensirion Holding AG
Also participating
business angelsexisting shareholders
About MaxWell Biosystems
Stage
Series A
Headquarters
Zurich, Switzerland
Founded
2016
Team Size
21–50
Sectors
healthneurosciencebiotechmicroelectronicssoftware_hardwareb2b